Lippert, O.: A market perspective on recent developments in the TRIPS and essential medicines debate. - S. 3-31 Scherer, F. M.; Watal, J.: The economics of TRIPS options for access to medicines. - S. 32-56 Maskus, K. E.; Ganslandt, M.: Parallel trade in pharmaceutical products: implications for procuring medicines for poor countries. - S. 57-80 Fatal side effects : medicine patents under the microscope. - S. 81-99 Bale, H. E.: Patents, patients and developing countries : access, innovation and the political dimension of trade policy. - S. 100-112 Cohen, J. C.. Developing states' responses to the pharmaceutical imperatives of the TRIPS Agreement. - S. 115-136 Granville, B.; Leonard, C.: The pharmaceutical sector : the generics development trajectory. - S. 137-160 Reekie, W. D.: The development trilemma and the South African response. - S. 161-177 Bermudez, J.: Expanding access to essential medicines in Brazil : recent economic regulation, policy-making and lessons learnt. - S. 178-197 Ocholo, D.: Cha